Related Experiment Video
Updated: Jun 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
[New oral anticoagulants: prospects]
1Service de médecine vasculaire et d'hypertension artérielle, Hôpital européen Georges-Pompidou, AP-HP, université Paris-Descartes, 75908 Paris Cedex 15. jean-noel.fiessinger@egp.aphp.fr
Two new oral anticoagulants, dabigatran and rivaroxaban, are approved for preventing venous thromboembolism after hip or knee surgery. These fixed-dose medications offer alternatives to traditional therapies, simplifying treatment regimens.
Area of Science:
- Pharmacology
- Clinical Medicine
- Thrombosis Research
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
